Laura Chico
Stock Analyst at Wedbush
(3.53)
# 892
Out of 4,981 analysts
221
Total ratings
45.03%
Success rate
6.55%
Average return
Main Sectors:
Stocks Rated by Laura Chico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DNTH Dianthus Therapeutics | Maintains: Outperform | $42 → $44 | $37.16 | +18.41% | 9 | Sep 12, 2025 | |
| TRML Tourmaline Bio | Downgrades: Neutral | $48 | $47.61 | +0.82% | 3 | Sep 9, 2025 | |
| JBIO Jade Biosciences | Maintains: Outperform | $17 → $18 | $7.72 | +133.16% | 3 | Aug 14, 2025 | |
| SLDB Solid Biosciences | Maintains: Outperform | $17 → $14 | $5.39 | +159.74% | 3 | Aug 13, 2025 | |
| STOK Stoke Therapeutics | Maintains: Outperform | $16 → $22 | $23.46 | -6.22% | 7 | Aug 13, 2025 | |
| XENE Xenon Pharmaceuticals | Maintains: Outperform | $42 → $43 | $36.20 | +18.80% | 9 | Aug 12, 2025 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $30 → $32 | $23.47 | +36.34% | 12 | Aug 7, 2025 | |
| GOSS Gossamer Bio | Maintains: Outperform | $4 → $5 | $3.46 | +44.51% | 6 | Aug 6, 2025 | |
| ARDX Ardelyx | Maintains: Outperform | $13 → $14 | $6.61 | +111.80% | 14 | Aug 5, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Outperform | $137 → $141 | $141.90 | -0.63% | 10 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $34 | $30.31 | +12.17% | 13 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $23.30 | -27.02% | 1 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $18 | $7.91 | +127.56% | 1 | Jun 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $15 | $3.93 | +281.68% | 2 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $130 | $137.27 | -5.30% | 1 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $121 | $144.86 | -16.47% | 18 | Jun 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $27 | $23.38 | +15.48% | 7 | Jun 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $4 | $3.89 | +2.83% | 4 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $30 | $14.19 | +111.42% | 8 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $34 → $26 | $23.77 | +9.38% | 8 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $26 → $28 | $37.71 | -25.74% | 7 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $43 | $14.24 | +201.97% | 10 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $3 | $1.26 | +138.10% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $28 | $7.43 | +276.85% | 9 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $29 | $24.85 | +16.70% | 14 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $12 | $1.48 | +710.81% | 10 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $7 | $4.18 | +67.46% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $42 | $18.87 | +122.63% | 7 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $11 | $0.60 | +1,730.89% | 4 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $6.09 | -17.90% | 5 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $54.09 | - | 5 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $5 | $3.07 | +62.87% | 2 | Aug 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $149 | $13.93 | +966.04% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $720 | $9.50 | +7,478.95% | 1 | Jan 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Strong Buy | $280 | $65.62 | +326.70% | 1 | Apr 21, 2017 |
Dianthus Therapeutics
Sep 12, 2025
Maintains: Outperform
Price Target: $42 → $44
Current: $37.16
Upside: +18.41%
Tourmaline Bio
Sep 9, 2025
Downgrades: Neutral
Price Target: $48
Current: $47.61
Upside: +0.82%
Jade Biosciences
Aug 14, 2025
Maintains: Outperform
Price Target: $17 → $18
Current: $7.72
Upside: +133.16%
Solid Biosciences
Aug 13, 2025
Maintains: Outperform
Price Target: $17 → $14
Current: $5.39
Upside: +159.74%
Stoke Therapeutics
Aug 13, 2025
Maintains: Outperform
Price Target: $16 → $22
Current: $23.46
Upside: -6.22%
Xenon Pharmaceuticals
Aug 12, 2025
Maintains: Outperform
Price Target: $42 → $43
Current: $36.20
Upside: +18.80%
Travere Therapeutics
Aug 7, 2025
Maintains: Outperform
Price Target: $30 → $32
Current: $23.47
Upside: +36.34%
Gossamer Bio
Aug 6, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $3.46
Upside: +44.51%
Ardelyx
Aug 5, 2025
Maintains: Outperform
Price Target: $13 → $14
Current: $6.61
Upside: +111.80%
Neurocrine Biosciences
Jul 31, 2025
Maintains: Outperform
Price Target: $137 → $141
Current: $141.90
Upside: -0.63%
Jul 14, 2025
Maintains: Neutral
Price Target: $35 → $34
Current: $30.31
Upside: +12.17%
Jul 8, 2025
Initiates: Outperform
Price Target: $17
Current: $23.30
Upside: -27.02%
Jun 30, 2025
Maintains: Outperform
Price Target: $16 → $18
Current: $7.91
Upside: +127.56%
Jun 24, 2025
Maintains: Outperform
Price Target: $17 → $15
Current: $3.93
Upside: +281.68%
Jun 18, 2025
Reiterates: Neutral
Price Target: $130
Current: $137.27
Upside: -5.30%
Jun 12, 2025
Reiterates: Neutral
Price Target: $121
Current: $144.86
Upside: -16.47%
Jun 5, 2025
Reiterates: Outperform
Price Target: $27
Current: $23.38
Upside: +15.48%
May 15, 2025
Reiterates: Neutral
Price Target: $4
Current: $3.89
Upside: +2.83%
May 7, 2025
Maintains: Outperform
Price Target: $32 → $30
Current: $14.19
Upside: +111.42%
May 7, 2025
Maintains: Neutral
Price Target: $34 → $26
Current: $23.77
Upside: +9.38%
May 5, 2025
Maintains: Underperform
Price Target: $26 → $28
Current: $37.71
Upside: -25.74%
Apr 21, 2025
Maintains: Outperform
Price Target: $43
Current: $14.24
Upside: +201.97%
Mar 12, 2025
Maintains: Outperform
Price Target: $4 → $3
Current: $1.26
Upside: +138.10%
Mar 12, 2025
Maintains: Outperform
Price Target: $27 → $28
Current: $7.43
Upside: +276.85%
Mar 3, 2025
Maintains: Neutral
Price Target: $30 → $29
Current: $24.85
Upside: +16.70%
Nov 8, 2024
Maintains: Outperform
Price Target: $19 → $12
Current: $1.48
Upside: +710.81%
Aug 7, 2024
Maintains: Neutral
Price Target: $8 → $7
Current: $4.18
Upside: +67.46%
Jul 29, 2024
Reiterates: Outperform
Price Target: $42
Current: $18.87
Upside: +122.63%
Apr 11, 2024
Maintains: Outperform
Price Target: $13 → $11
Current: $0.60
Upside: +1,730.89%
Mar 20, 2024
Reiterates: Neutral
Price Target: $5
Current: $6.09
Upside: -17.90%
Sep 28, 2023
Initiates: Market Perform
Price Target: n/a
Current: $54.09
Upside: -
Aug 12, 2022
Maintains: Outperform
Price Target: $9 → $5
Current: $3.07
Upside: +62.87%
Aug 8, 2022
Downgrades: Neutral
Price Target: $149
Current: $13.93
Upside: +966.04%
Jan 19, 2018
Initiates: Outperform
Price Target: $720
Current: $9.50
Upside: +7,478.95%
Apr 21, 2017
Initiates: Strong Buy
Price Target: $280
Current: $65.62
Upside: +326.70%